The RADIOTRANSNET project is a French initiative for the structuration of preclinical research in the field of radiation oncology in France. It has been submitted by the French Society of Radiation Oncology (SFRO) and the French society of medical physics (SFPM). It has been favorably evaluated by the International Evaluation Committee of INCa (the French Cancer Institute). RADIOTRANSNET network has officially been launched at the end of 2018.
Research and Innovation in optimized medical applications of ionizing radiation aim to improve patient care and quality of life. The ambition of RADIOTRANSNET is to propose a robust methodology of science-based consensus aiming 1) to build a national research consortium dedicated to radiation oncology, 2) to implement a strategic research agenda (SRA) based on rigorous scientific and medical state of the art in radiotherapy and radiobiology, and 3) to define a road map to favor existing scientific and clinical interactions.
Four main strategies (4 workpackages) have been identified to improve therapeutic index of radiotherapy and define RADIOTRANSNET network activities:
- WP1: Optimizing the specificity of the dose distribution of radiotherapy treatments,
- WP2: Decreasing radiotherapy side effects on normal tissue,
- WP3: Combining new molecular targeted agents and biological modifiers,
- WP4: Optimizing dose modelling and treatment planning
This Fourth RadioTransNet Workshop, organized in partnership with the "Tumour Targeting, Imaging, Radiotherapies" network from Cancéropole Grand Ouest, is dedicated to the Workpackage 3 of the project and aims defining strategies for optimized development of combined treatment with radiotherapy for cancer treatment. Indeed, The use of new molecular targeted agents and biological modifiers with radiation therapy may increase the anti-tumor efficacy and/or decrease the radiation effects on normal tissues, i.e. increase the therapeutic ratio and enlarge the therapeutic window. Proofs of concept have been obtained by targeting microenvironment such as hypoxia or immune cells. However, if combining drugs with irradiation could be more effective than radiotherapy alone, it may also be more toxic, indicating an absolute need for faster and earlier evaluation of the combined treatments that requires extensive researches for a better understanding of cancer biology and molecular response to ionizing radiation.
This Workshop aims, through several oral presentations, to draw up an inventory of current practices and emerging methods in order to address the key issues and to identify the needs. Then, a “working groups” session will allow reflections and exchanges to start the structuration process in order to define an adapted research program within the RadioTransNet Network.
Registration
Registration is free but mandatory to attend the workshop.
The deadline for registration is December 8th of 2020, 17h
To attend this workshop, please proceed to the registration using the online form.
You can already contribute to working groups submitting an abtract. Summaries may include research priorities, short program, existing collaborations (academic and/or industrial) or any suggestion related to round tables issues.
Looking forward to seeing you,
The RadioTransNet Workpackage 3 team,
S. Pinel, S. Supiot, JN Badel & E. Bayart
Chargement... 
